Business context and reporting period
The supplied filing is Virios Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2024, not a filing identified as Dogwood Therapeutics, Inc. Verify the issuer before relying on this summary. Virios is a pre-revenue biotechnology company developing IMC-1 for fibromyalgia and IMC-2 for Long-COVID.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 or prior period |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1.314 million | $1.557 million |
| Net loss | $1.291 million | $1.517 million |
| Net loss per share, basic and diluted | $0.07 | $0.08 |
| Net cash used in operations | $0.937 million | $1.698 million |
| Cash at period end | $2.380 million | $3.317 million at Dec. 31, 2023 |
| Current liabilities | $0.570 million | $0.359 million at Dec. 31, 2023 |
| Debt | No debt outstanding | No debt outstanding |
Research and development expense fell to $0.344 million from $0.498 million, mainly due to lower toxicology and regulatory consulting costs. General and administrative expense declined to $0.970 million from $1.060 million, primarily due to lower public-company insurance expense. With no revenue, gross margin is not applicable. The filing reports no income tax provision.
Material changes and outlook
- Cash declined $0.937 million during the quarter. Management says available cash is insufficient for at least the next 12 months and additional capital will be needed within three to five months; the filing states substantial doubt exists about the company’s ability to continue as a going concern.
- Management plans to pursue equity or debt financing, partnerships, licensing, or other funding. Financing may be unavailable or on unfavorable terms; equity issuance would dilute shareholders, and a shortfall could delay development and clinical trials.
- Management reported encouraging results from an earlier open-label Long-COVID study of valacyclovir plus celecoxib, but the results are not from the ongoing randomized, double-blind, placebo-controlled study. Results were expected in the second half of 2024.
- The prior FORTRESS fibromyalgia study did not meet its prespecified primary endpoint (p=0.302). The company cites a favorable post-hoc subgroup analysis and is exploring a partner to advance IMC-1; FDA feedback was described as supportive of the proposed Phase 3 program, subject to review of chronic toxicology work.
- FDA feedback on a proposed IMC-2 Phase 2b study was received in December 2023. Planned work includes a potential IND submission and continued funding of the investigator-sponsored Long-COVID study.
- Nasdaq notified the company on May 1, 2024 that it remained noncompliant with the $1 minimum bid-price requirement. A hearing was scheduled for June 18, 2024; the hearing request stayed delisting pending the panel’s decision. Management said its proposed compliance plan could include a reverse stock split.
- Effective March 1, 2024, employees accepted a 10% salary reduction in exchange for future-vesting options, and directors accepted a 10% fee reduction. No material pending litigation or off-balance-sheet arrangements were reported.
Important facts to verify
- Confirm the issuer: the source document names Virios Therapeutics, Inc., whereas the request metadata names Dogwood Therapeutics, Inc.
- Verify the company’s current cash position, financing plans, and ability to fund operations beyond the stated three-to-five-month capital need.
- Check the outcome of the Nasdaq hearing and any subsequent listing-compliance actions.
- Review subsequent clinical-trial results and regulatory developments for IMC-1 and IMC-2; reported earlier Long-COVID findings were exploratory and open-label.